论文部分内容阅读
目的观察前列地尔联合羟苯磺酸钙辅治糖尿病肾病的临床疗效。方法将218例糖尿病肾病患者随机分为观察组和对照组各109例。观察组给予前列地尔联合羟苯磺酸钙治疗,对照组给予羟苯磺酸钙治疗。比较2组临床疗效及治疗前后2组24h尿白蛋白排泄率的变化。结果观察组总有效率为94.50%高于对照组的80.73%,差异有统计学意义(P<0.05)。治疗前,2组患者的24h尿白蛋白排泄率比较差异无统计学意义(P<0.05);治疗后2组患者24h尿白蛋白排泄率较治疗前均下降,并且观察组患者24h尿白蛋白排泄率低于对照组,差异均有统计学意义(P<0.05)。结论前列地尔联合羟苯磺酸钙辅治糖尿病肾病具有很好的临床疗效,值得临床推广。
Objective To observe the clinical efficacy of alprostadil in combination with calcium dobesilate in the treatment of diabetic nephropathy. Methods 218 patients with diabetic nephropathy were randomly divided into observation group and control group, 109 cases each. The observation group was given alprostadil combined with calcium dobesilate, and the control group was given calcium dobesilate. The clinical efficacy of two groups were compared before and after treatment 24h urinary albumin excretion rate changes. Results The total effective rate of the observation group was 94.50% higher than that of the control group (80.73%), the difference was statistically significant (P <0.05). Before treatment, urinary albumin excretion rate of 24 hours in two groups had no significant difference (P <0.05); 24h urinary albumin excretion rate decreased in both groups after treatment, and 24h urinary albumin Excretion rate was lower than the control group, the difference was statistically significant (P <0.05). Conclusion Alprostadil combined with calcium dobesilate in the treatment of diabetic nephropathy has good clinical efficacy, worthy of clinical promotion.